EGFR and non-small cell lung carcinoma: The prognosis of patients with advanced non-small cell lung cancer (NSCLC) is poor, and their 1-year survival rate after cytotoxic chemotherapy is only 29%.[1] However, the development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) dramatically improves the prognosis of certain patients.